Rituximab infusion orders

Reading File

Checking Date & Time

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Searching the Web

rituximab infusion orders premedication rate titration protocol 2024

Searching the Web

rituximab infusion order set premedication standard protocol oncology rheumatology

Finding Sources

Here is a comprehensive reference for Rituximab (Rituxan) Infusion Orders, covering preparation, premedication, infusion rates, monitoring, and adverse event management.

Rituximab Infusion Orders

1. Indication-Based Dosing

Indication	Dose	Schedule
NHL (single agent)	375 mg/m² IV	Weekly × 4 doses; maintenance q3–6 months
NHL (+ chemotherapy, e.g., R-CHOP)	375 mg/m² IV	Every 3–4 weeks, up to 8 doses
CLL	375 mg/m² (cycle 1), then 500 mg/m²	Every 28 days
RA	1,000 mg IV	Days 1 and 15 (repeat q16–24 weeks)
GPA/MPA (ANCA vasculitis)	375 mg/m² IV	Weekly × 4; or 1,000 mg × 2 (days 1 and 15)
Pemphigus/autoimmune	1,000 mg IV	Days 1 and 15

2. Preparation

Dilute in 0.9% NaCl or D5W to a final concentration of 1–4 mg/mL
Do not shake; gently invert bag to mix
Administer via dedicated IV line — do not mix with other drugs

3. Premedication (Required Before Each Infusion)

Administer 30 minutes prior to infusion:

Agent	Dose	Route	Purpose
Acetaminophen	650–1,000 mg	PO	Antipyretic
Diphenhydramine (Benadryl)	25–50 mg	IV or PO	Antihistamine
Methylprednisolone	100 mg	IV	Reduces infusion reactions (especially for RA/autoimmune indications)

Note: For lymphoma indications, methylprednisolone 100 mg IV (or hydrocortisone 100 mg IV) is standard. For RA, methylprednisolone 100 mg IV is required per labeling. Corticosteroids can be omitted for subsequent doses in some institutions if the patient tolerated the first infusion without reaction.

Antihypertensives: Consider holding antihypertensive medications 12 hours before rituximab (hypotension is a known infusion reaction; BP may need to be managed without medications on-board).

4. Infusion Rate Protocol

First Infusion (Dose 1)

Time	Rate	Cumulative Time
Start	50 mg/hr	0–30 min
If no reaction →	100 mg/hr	30–60 min
If no reaction →	150 mg/hr	60–90 min
If no reaction →	200 mg/hr	90–120 min
If no reaction →	250 mg/hr	120–150 min
Maximum rate →	400 mg/hr	Until complete

Increment: +50 mg/hr every 30 minutes as tolerated
Maximum rate: 400 mg/hr

Subsequent Infusions (Doses 2+)

If first infusion was well tolerated (no reaction):
- Start at 100 mg/hr
- Increase by 100 mg/hr every 30 minutes
- Maximum 400 mg/hr

Accelerated 90-Minute Infusion (Selected Patients)

Eligible for patients who have completed ≥1 full-dose infusion without reaction
Administer 20% of total dose over 30 minutes, then 80% over 60 minutes
Not recommended for patients with high circulating lymphocyte counts (CLL) or prior reactions

5. Tumor Lysis Syndrome (TLS) Precautions — CLL / High Tumor Burden

Initial dose: cap at 50 mg/m² on Day 1 if high circulating tumor cell burden
Administer allopurinol starting 12–24 hours before infusion
Ensure adequate IV hydration before and during infusion
Monitor uric acid, potassium, phosphate, creatinine during/after infusion

6. Monitoring During Infusion

Parameter	Timing
Vital signs (BP, HR, SpO₂, temp)	Baseline, then every 15–30 minutes
Symptoms of infusion reaction	Continuous nursing assessment
CBC, LFTs, hepatitis B status	Before first dose (see pre-treatment workup)

7. Infusion Reaction Management

Severity	Symptoms	Action
Mild–Moderate	Fever, chills, urticaria, pruritus, mild hypotension	Stop or slow infusion to 50% of current rate; give additional diphenhydramine ± acetaminophen; resume when resolved
Severe	Severe hypotension, bronchospasm, angioedema, anaphylaxis	Stop infusion immediately; give epinephrine 0.3 mg IM, diphenhydramine IV, hydrocortisone IV, supportive care
Death	Hypoxia, ARDS (reported within 24 hrs)	Permanent discontinuation; critical care

Infusion reactions occur most commonly during the first infusion and in the first 30–120 minutes. With premedication, most are mild. — Goodman & Gilman's Pharmacological Basis of Therapeutics

8. Pre-Treatment Workup

Before starting rituximab:

Hepatitis B serology (HBsAg, HBsAb, HBcAb) — rituximab can reactivate HBV; prophylactic antiviral therapy required if positive
CBC with differential and platelets
LFTs / comprehensive metabolic panel
Immunoglobulin levels (baseline IgG, especially for repeated courses)
Consider JC virus risk assessment for prolonged immunosuppression

9. Post-Infusion Observations

Observe patient for 30–60 minutes after infusion completion
Counsel on signs of delayed reactions: fever, rash, new respiratory symptoms
Counsel on infection risk (immunosuppression, hypogammaglobulinemia)

10. Key Warnings (Black Box)

Warning	Details
Fatal Infusion Reactions	Deaths within 24 hours reported; discontinue for severe reactions
Hepatitis B Reactivation	Screen all patients; can cause fulminant hepatitis and death
Progressive Multifocal Leukoencephalopathy (PML)	JC virus reactivation; fatal/disabling; monitor for new neurological symptoms
Severe Mucocutaneous Reactions	Stevens-Johnson syndrome reported; discontinue if occurs

Sources

Goodman & Gilman's The Pharmacological Basis of Therapeutics — Rituximab (CD20)
Lippincott Illustrated Reviews: Pharmacology — Clinical Application 38.1 & Section H
UofL Health Rituximab-abbs (Truxima) Order Set (Apr 2024)
Kaiser Permanente RiTUXimab Infusion Therapy Plan Orders
PeaceHealth RIC Infusion Guidelines (Dec 2024)

Clinical note: Specific order sets vary by institution and indication (oncology vs. rheumatology vs. neurology). Always verify against your institutional formulary — biosimilars (e.g., rituximab-abbs/Truxima, rituximab-pvvr/Ruxience) follow the same infusion protocols as the originator.

1 gram infusion should be given as how

Based on the sources already in context (including the Kaiser Permanente and institutional order sets), here is the 1,000 mg (1 gram) Rituximab Infusion Protocol:

Rituximab 1,000 mg IV Infusion Orders

Preparation

Dilute 1,000 mg in 500 mL NS (0.9% NaCl) → final concentration 2 mg/mL
Gentle inversion to mix; do not shake

Premedication (30 minutes before infusion)

Drug	Dose	Route
Acetaminophen	1,000 mg	PO
Diphenhydramine	50 mg	IV or PO
Methylprednisolone	100 mg	IV push

Infusion Rate — First Dose (Dose 1)

Step	Rate	Duration
Start	50 mg/hr	30 min
Step up	100 mg/hr	30 min
Step up	150 mg/hr	30 min
Step up	200 mg/hr	30 min
Step up	300 mg/hr	30 min
Maximum	400 mg/hr	Until complete

Increment: +50 mg/hr every 30 min if no reaction
Maximum rate: 400 mg/hr
Total infusion time: ~4–5 hours (first dose)

Infusion Rate — Second Dose Onward (if first dose tolerated)

Step	Rate	Duration
Start	100 mg/hr	30 min
Step up	200 mg/hr	30 min
Step up	300 mg/hr	30 min
Maximum	400 mg/hr	Until complete

Total infusion time: ~3–4 hours

Common Use Cases for the 1g Dose

Indication	Schedule
Rheumatoid Arthritis	1,000 mg on Day 1 and Day 15, then repeat every 16–24 weeks
ANCA Vasculitis (GPA/MPA)	1,000 mg on Day 1 and Day 15
Pemphigus vulgaris	1,000 mg on Day 1 and Day 15

Infusion Reaction — Response

Reaction	Action
Mild (flushing, chills, urticaria)	Slow rate to 50% of current rate; extra diphenhydramine; resume when resolved
Moderate (mild hypotension, dyspnea)	Stop infusion; treat; resume at half rate when stable
Severe (anaphylaxis, severe bronchospasm)	Stop permanently; epinephrine 0.3 mg IM, hydrocortisone 200 mg IV, airway support

Key Points

The 1g dose is the standard for RA and autoimmune indications (not weight-based)
Methylprednisolone 100 mg IV premedication is specifically required in the RA indication per the prescribing information — it reduces both infusion reactions and disease flare
Hold antihypertensives 12 hours before to reduce hypotension risk during the infusion
Monitor vitals every 15–30 minutes throughout

This is a shared conversation. Sign in to Orris to start your own chat.